Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis

被引:74
作者
Rafati, S
Zahedifard, F
Nazgouee, F
机构
[1] Inst Pasteur, Mol Immunol & Vaccine Res Lab, Tehran, Iran
[2] Inst Pasteur, Clin Res Unit, Tehran, Iran
关键词
cysteine proteinase type I and II; prime-boost vaccination; Leishmania infantum;
D O I
10.1016/j.vaccine.2005.11.011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vaccination with a cocktail of DNA encoding cysteine proteinases has been previously shown to confer protection against experimental cutaneous leishmaniasis (CL). In the present study we test the efficacy of immunization against Leishmania infantum in a murine model of infection, using a prime-boost strategy. BALB/c mice were immunized twice, in a 3 weeks interval, with cocktail of plasmids DNA encoding type I (cpb) and II (cpa) cysteine proteinases. DNA immunization was then followed by a boost with rCPA/rCPB in addition to CpG ODN and Montanide720 as adjuvant. Analysis of the immune response showed that vaccination mainly elicited antigen-specific IgG2a antibodies, suggesting the induction of a Th1 immune response. This was further confirmed by the analysis of the splenic cytokine production: at all time points the ratio of IFN-gamma/IL-5 induced upon restimulation with rCPA and rCPB was always significantly higher in vaccinated group compared to both control groups. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2169 / 2175
页数:7
相关论文
共 33 条
[1]  
BABALOO Z, 1999, IMMUNOL LETT, V65, P105
[2]   Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN) [J].
Borj-Cabrera, GP ;
Pontes, NNC ;
da Silva, VO ;
de Souza, EP ;
Santos, WR ;
Gomes, EM ;
Luz, KG ;
Palatnik, M ;
de Sousa, CBP .
VACCINE, 2002, 20 (27-28) :3277-3284
[3]   CULTURE MICROTITRATION - A SENSITIVE METHOD FOR QUANTIFYING LEISHMANIA-INFANTUM IN TISSUES OF INFECTED MICE [J].
BUFFET, PA ;
SULAHIAN, A ;
GARIN, YJF ;
NASSAR, N ;
DEROUIN, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (09) :2167-2168
[4]   IL-10 leads to a higher parasite persistence in a resistant mouse model of Leishmania major infection [J].
da Costa, AV ;
Huerre, M ;
Delacre, M ;
Auriault, C ;
Costa, JMC ;
Verwaerde, C .
PARASITOLOGY INTERNATIONAL, 2002, 51 (04) :367-379
[5]   A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN) [J].
da Silva, VO ;
Borja-Cabrera, GP ;
Pontes, NNC ;
de Souza, EP ;
Luz, KG ;
Palatnik, M ;
de Sousa, CBP .
VACCINE, 2000, 19 (9-10) :1082-1092
[6]   Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters [J].
Fragaki, K ;
Suffia, I ;
Ferrua, B ;
Rousseau, D ;
Le Fichoux, Y ;
Kubar, J .
VACCINE, 2001, 19 (13-14) :1701-1709
[7]   Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections [J].
Ghosh, A ;
Zhang, WW ;
Matlashewski, G .
VACCINE, 2001, 20 (1-2) :59-66
[8]   Leishmaniasis: Current status of vaccine development [J].
Handman, E .
CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (02) :229-+
[9]  
KAYE PM, 1991, J IMMUNOL, V146, P2763
[10]   Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis:: a randomised, double-blind, BCG-controlled trial in Sudan [J].
Khalil, EAG ;
El Hassan, AM ;
Zijlstra, EE ;
Mukhtar, MM ;
Ghalib, HW ;
Musa, B ;
Ibrahim, ME ;
Kamil, AA ;
Elsheikh, M ;
Babiker, A ;
Modabber, F .
LANCET, 2000, 356 (9241) :1565-1569